Avalyn Pharma Inc. AVLN
$28.51
▲ +7.16% 24H
About
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline features optimized inhaled formulations of established antifibrotic medicines, such as AP01, an inhaled version of …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees50
TickerAVLN
Statistics
Market Cap$1.19B
Revenue (TTM)—
Net Income—
Net Margin—
EPS—
P/E-13.85
P/S—
P/B-4.47
EV/EBITDA-13.08
ROE-68.3%
Dividend Yield—
Price$28.51
Data: Twelve Data · Revenue = mcap / P/S